Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence.
- Author:
Xian-Yan-Ling YI
1
;
De-Hong CAO
1
;
Ping-Hong YOU
2
;
Xing-Yu XIONG
1
;
Xiao-Nan ZHENG
1
;
Ge PENG
3
;
Da-Zhou LIAO
1
;
Hong LI
1
;
Lu YANG
1
;
Jian-Zhong AI
1
Author Information
- Publication Type:Journal Article
- Keywords: chemotherapy regimen; locally advanced penile cancer; neoadjuvant chemotherapy; response rate
- MeSH: Antineoplastic Combined Chemotherapy Protocols/therapeutic use*; Humans; Male; Neoadjuvant Therapy/methods*; Penile Neoplasms/drug therapy*; Platinum; Treatment Outcome
- From: Asian Journal of Andrology 2022;24(2):180-185
- CountryChina
- Language:English
- Abstract: Neoadjuvant chemotherapy (NAC) has shown promising results in patients with locally advanced penile cancer. However, no consensus exists on its applications for locally advanced penile cancer. Thus, it is unclear which kind of chemotherapy regimen is the best choice. Consequently, a systematic search of PubMed, Web of Science, and EMBASE was performed in March 2021 to assess the efficacy and safety of NAC for the treatment of patients with locally advanced penile cancer. The Newcastle-Ottawa Scale was used to assess the risk of bias in each study. This study synthesized 14 published studies. The study revealed that patients who achieved an objective response to NAC obtained a better survival outcome compared with those who did not achieve an objective response. In addition, the objective response rates (ORRs) and pathological complete response (pCR) rates were 0.57 and 0.11, respectively. The incidence of grade ≥3 toxicity was 0.36. Subgroup analysis found that the ORR and pCR of the taxane-platinum (TP) regimen group performed better than those of the nontaxane-platinum (NTP) regimen group (0.57 vs 0.54 and 0.14 vs 0.07, respectively). Moreover, the TP regimen group had more frequent toxicity than the NTP regimen group (0.41 vs 0.26). However, further studies were warranted to confirm the findings.
